Hye Soon Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hye Soon Kim has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Eugene Han
Department of Internal Medicine Keimyung University, School of Medicine Daegu Republic of Korea
6 shared publications Mi Kyung Kim
Department of Internal Medicine, Keimyung University, School of Medicine, Dongsan Hospital, Daegu 42601, Republic of Korea
6 shared publicationsNan Hee Cho
Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea
5 shared publications- Mi Kyung Kim
Division of Endocrinology, Department of Internal Medicine, Inje University Haeundae Paik Hospital, Busan, Korea
4 shared publications - Byung-Wan Lee
Department of Internal Medicine Yonsei University College of Medicine Seoul Republic of Korea
3 shared publications Eugene Han
Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Republic of Korea
3 shared publications
Latest Publications
- Open Access
- 13 March 2026
- Published by Korean Society for the Study of Obesity in Journal of Obesity & Metabolic Syndrome
- Vol. 35 (2) , 150-163
Evaluating the Safety Profile of Glucagon-Like Peptide-1 Receptor Agonists: Adverse Events and Clinical Recommendations
Mi Kyung Kim, Eun Yeong Ha, Hye Soon Kim. J Obes Metab Syndr -0001;0:0-. https://doi.org/10.7570/jomes25081
- 13 March 2026
- Published by Korean Society for the Study of Obesity in Journal of Obesity & Metabolic Syndrome
- Vol. 35 (2) , 150-163
Open AccessEvaluating the Safety Profile of Glucagon-Like Peptide-1 Receptor Agonists: Adverse Events and Clinical Recommendations
Mi Kyung Kim, Eun Yeong Ha, Hye Soon Kim. J Obes Metab Syndr -0001;0:0-. https://doi.org/10.7570/jomes25081
- Open Access
- 29 July 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (10) , 5727-5736
Efficacy and safety of lobeglitazone added to metformin and sitagliptin combination therapy in patients with type 2 diabetes: A 52‐week, multicentre, randomized, placebo‐controlled, phase III clinical trial
Aims: To evaluate the efficacy and safety of adding lobeglitazone to a triple therapy regimen in Korean patients with type 2 diabetes whose blood glucose levels were inadequately controlled despite dual therapy with metformin and sitagliptin. Materials and Methods: This randomised, double‐blind, placebo‐controlled, phase 3 study involved 231 Korean patients with type 2 diabetes whose HbA1c levels ranged from 7.0% to 10.0% despite treatment with metformin (≥1000 mg/day) and sitagliptin (100 mg/day). Participants received lobeglitazone (0.5 mg/day) or placebo for 24 weeks, followed by a 28‐week open‐label phase in which all patients received lobeglitazone. The primary endpoint was the change in glycated haemoglobin (HbA1c) at 24 weeks; secondary endpoints included changes in fasting plasma glucose (FPG), homeostatic model assessment for insulin resistance (HOMA‐IR), HOMA for β‐cell function (HOMA‐β), quantitative insulin‐sensitivity check index (QUICKI) and lipid profile. Safety assessments were also conducted. Results: At week 24, lobeglitazone treatment demonstrated a significantly greater reduction in HbA1c compared with placebo (−1.00% ± 0.09% vs. 0.02% ± 0.09%), with a between‐group difference in the adjusted mean change [−1.03%; p < 0.0001]. Additionally, lobeglitazone significantly reduced FPG compared with placebo at week 24 and improved HOMA‐IR, HOMA‐β and QUICKI. Lipid parameters were also improved by lobeglitazone administration. Adverse events were similar in both treatment arms. Conclusions: The addition of lobeglitazone in patients with type 2 diabetes inadequately controlled with metformin and sitagliptin is a beneficial therapeutic option, not only providing effective glycaemic control but also improving insulin function such as sensitivity and enhancing certain lipid parameters.
- 29 July 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (10) , 5727-5736
Open AccessEfficacy and safety of lobeglitazone added to metformin and sitagliptin combination therapy in patients with type 2 diabetes: A 52‐week, multicentre, randomized, placebo‐controlled, phase III clinical trial
Aims: To evaluate the efficacy and safety of adding lobeglitazone to a triple therapy regimen in Korean patients with type 2 diabetes whose blood glucose levels were inadequately controlled despite dual therapy with metformin and sitagliptin. Materials and Methods: This randomised, double‐blind, placebo‐controlled, phase 3 study involved 231 Korean patients with type 2 diabetes whose HbA1c levels ranged from 7.0% to 10.0% despite treatment with metformin (≥1000 mg/day) and sitagliptin (100 mg/day). Participants received lobeglitazone (0.5 mg/day) or placebo for 24 weeks, followed by a 28‐week open‐label phase in which all patients received lobeglitazone. The primary endpoint was the change in glycated haemoglobin (HbA1c) at 24 weeks; secondary endpoints included changes in fasting plasma glucose (FPG), homeostatic model assessment for insulin resistance (HOMA‐IR), HOMA for β‐cell function (HOMA‐β), quantitative insulin‐sensitivity check index (QUICKI) and lipid profile. Safety assessments were also conducted. Results: At week 24, lobeglitazone treatment demonstrated a significantly greater reduction in HbA1c compared with placebo (−1.00% ± 0.09% vs. 0.02% ± 0.09%), with a between‐group difference in the adjusted mean change [−1.03%; p < 0.0001]. Additionally, lobeglitazone significantly reduced FPG compared with placebo at week 24 and improved HOMA‐IR, HOMA‐β and QUICKI. Lipid parameters were also improved by lobeglitazone administration. Adverse events were similar in both treatment arms. Conclusions: The addition of lobeglitazone in patients with type 2 diabetes inadequately controlled with metformin and sitagliptin is a beneficial therapeutic option, not only providing effective glycaemic control but also improving insulin function such as sensitivity and enhancing certain lipid parameters.
- Open Access
- 19 December 2024
- Published by The Korean Society of Applied Pharmacology in Biomolecules & Therapeutics
- Vol. 33 (1) , 5-17
An Overview of Existing and Emerging Weight-Loss Drugs to Target Obesity-Related Complications: Insights from Clinical Trials
Mi Kyung Kim and Hye Soon Kim. Biomolecules & Therapeutics 2025;33:5-17. https://doi.org/10.4062/biomolther.2024.228
- 19 December 2024
- Published by The Korean Society of Applied Pharmacology in Biomolecules & Therapeutics
- Vol. 33 (1) , 5-17
Open AccessAn Overview of Existing and Emerging Weight-Loss Drugs to Target Obesity-Related Complications: Insights from Clinical Trials
Mi Kyung Kim and Hye Soon Kim. Biomolecules & Therapeutics 2025;33:5-17. https://doi.org/10.4062/biomolther.2024.228
- Open Access
- 30 September 2024
- Published by Korean Diabetes Association in Diabetes & Metabolism Journal
- Vol. 48 (5) , 882-884
Ideal Combination of Oral Hypoglycemic Agents for Patients with Type 2 Diabetes Mellitus
- 30 September 2024
- Published by Korean Diabetes Association in Diabetes & Metabolism Journal
- Vol. 48 (5) , 882-884
Open AccessIdeal Combination of Oral Hypoglycemic Agents for Patients with Type 2 Diabetes Mellitus
- Open Access
- 21 March 2024
- Published by Springer Nature in Advances in Therapy
- Vol. 41 (5) , 1967-1982
Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300 Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study
Introduction The TOujeo BEyond glucose control (TOBE) study evaluated clinical outcomes with insulin glargine 300 units/mL (Gla-300) in insulin-naïve Korean people with type 2 diabetes mellitus (T2DM) in a real-world setting. Methods This 24-week, prospective, non-interventional, multicenter, open-label, single-arm, observational study included adults aged ≥ 20 years with T2DM suboptimally controlled with oral hypoglycemic agents and/or glucagon-like peptide 1 receptor agonists who require basal insulin. Eligible participants were assigned to either general target glycated hemoglobin (HbA1c < 7%) or individualized target groups as per physician’s discretion considering guidelines and participants’ characteristics. The primary endpoint was the proportion of participants achieving the HbA1c target (individualized or general) at 24 weeks. Results Among 369 participants, 19.5% (72/369) of participants achieved the HbA1c target at week 24; 37.5% (33/88) in the individualized and 13.9% (39/281) in the general target group. In both target groups, similar reductions in fasting plasma glucose and body weight were observed, with low incidence of hypoglycemia, and T2DM duration was significantly shorter in participants who did versus those who did not achieve the target HbA1c (individualized target group: 9.6 ± 8.0 versus 13.1 ± 8.4 years, P = 0.0454; general target group: 10.2 ± 8.6 versus 12.8 ± 7.4 years, P = 0.0378). Conclusions This study showed that initiation of insulin therapy with Gla-300 in people with T2DM using an individualized approach is more effective in achieving an HbA1c target. Moreover, earlier initiation of insulin therapy in people with suboptimally controlled T2DM may increase the success rate of glycemic control. A graphical abstract is available with this article. Graphical Abstract
- 21 March 2024
- Published by Springer Nature in Advances in Therapy
- Vol. 41 (5) , 1967-1982
Open AccessReal-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300 Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study
Introduction The TOujeo BEyond glucose control (TOBE) study evaluated clinical outcomes with insulin glargine 300 units/mL (Gla-300) in insulin-naïve Korean people with type 2 diabetes mellitus (T2DM) in a real-world setting. Methods This 24-week, prospective, non-interventional, multicenter, open-label, single-arm, observational study included adults aged ≥ 20 years with T2DM suboptimally controlled with oral hypoglycemic agents and/or glucagon-like peptide 1 receptor agonists who require basal insulin. Eligible participants were assigned to either general target glycated hemoglobin (HbA1c < 7%) or individualized target groups as per physician’s discretion considering guidelines and participants’ characteristics. The primary endpoint was the proportion of participants achieving the HbA1c target (individualized or general) at 24 weeks. Results Among 369 participants, 19.5% (72/369) of participants achieved the HbA1c target at week 24; 37.5% (33/88) in the individualized and 13.9% (39/281) in the general target group. In both target groups, similar reductions in fasting plasma glucose and body weight were observed, with low incidence of hypoglycemia, and T2DM duration was significantly shorter in participants who did versus those who did not achieve the target HbA1c (individualized target group: 9.6 ± 8.0 versus 13.1 ± 8.4 years, P = 0.0454; general target group: 10.2 ± 8.6 versus 12.8 ± 7.4 years, P = 0.0378). Conclusions This study showed that initiation of insulin therapy with Gla-300 in people with T2DM using an individualized approach is more effective in achieving an HbA1c target. Moreover, earlier initiation of insulin therapy in people with suboptimally controlled T2DM may increase the success rate of glycemic control. A graphical abstract is available with this article. Graphical Abstract
- Open Access
- 1 January 2023
- Published by XMLink in Journal of Metabolic and Bariatric Surgery
- Vol. 12 (2) , 26-34
Strategies to Maintain the Remission of Diabetes Following Metabolic Surgery
Kim MK, et al. J Metab Bariatr Surg. 2023 Dec;12(2):26-34. https://doi.org/10.17476/jmbs.2023.12.2.26
- 1 January 2023
- Published by XMLink in Journal of Metabolic and Bariatric Surgery
- Vol. 12 (2) , 26-34
Open AccessStrategies to Maintain the Remission of Diabetes Following Metabolic Surgery
Kim MK, et al. J Metab Bariatr Surg. 2023 Dec;12(2):26-34. https://doi.org/10.17476/jmbs.2023.12.2.26
- Open Access
- 1 November 2022
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 17 (3) , 456-465
High Sodium Intake, as Assessed by Urinary Sodium Excretion, Is Associated with Nonalcoholic Fatty Liver Disease or Sarcopenia
Eugene Han, Mi Kyung Kim, Seung-Soon Im, Hye Soon Kim, Taeg Kyu Kwon, and Byoung Kuk Jang. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl220133
- 1 November 2022
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 17 (3) , 456-465
Open AccessHigh Sodium Intake, as Assessed by Urinary Sodium Excretion, Is Associated with Nonalcoholic Fatty Liver Disease or Sarcopenia
Eugene Han, Mi Kyung Kim, Seung-Soon Im, Hye Soon Kim, Taeg Kyu Kwon, and Byoung Kuk Jang. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl220133
- 1 July 2022
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 36 (8) , 108253
Non-alcoholic fatty liver disease and sarcopenia is associated with the risk of albuminuria independent of insulin resistance, and obesity
- 1 July 2022
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 36 (8) , 108253
Non-alcoholic fatty liver disease and sarcopenia is associated with the risk of albuminuria independent of insulin resistance, and obesity
- Open Access
- 1 May 2022
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 15, 1495-1503
Real-World Analysis of Rapid-Acting Insulin Analog Use and Its Blood Glucose Lowering Effect in Patients with Type 2 Diabetes Mellitus: Results from PASSION Disease Registry in Korea
Purpose: Although rapid-acting insulins (RAIs) are used frequently in Korean clinical settings, evidence on their use is limited. This study explores the pattern and clinical effectiveness of the use of RAIs in Korean patients with type 2 diabetes mellitus (T2DM). Patients and Methods: This non-interventional, observational study enrolled patients (aged > 18 years) with T2DM who were prescribed RAIs. The pattern of use and effectiveness of RAI analogs were evaluated over 6 months. Results: A total of 299/451 patients were analyzed. Approximately 90% (n/N=270/299) of the patients received insulin glulisine, which significantly reduced their levels of glycated hemoglobin (HbA1c: n=270, mean± standard deviation [SD]; − 1.16± 6.02%, p=0.0017), fasting plasma glucose (n=40; mean±SD: − 54.9± 90.89 mg/dl, p=0.0005), and post prandial blood glucose (n=35, mean±SD: − 89.46± 105.68 mg/dl, p< 0.0001) at 6 months, with a corresponding increase in body weight (BW) (n=197, mean±SD:1.45± 3.64 kg, p< 0.0001). At 6 months, more patients receiving an intensive regimen (basal insulin+≥ 2 RAI injections/day) had HbA1c < 7% than those receiving a non-intensive regimen (basal insulin+1 RAI injection/day) (20.69% vs 7.46%; p=0.0333); the corresponding reduction in HbA1c was also higher in patients receiving the intensive regimen (p< 0.0001). About one-fourth patients (n/N=22/95) were switched to the intensive regimen (from 1 to ≥ 2 RAI injections/day), and only 4.41% (n/N=9/204) of the patients were switched to 1 RAI injection/day. The patients receiving the intensive regimen showed higher levels of HbA1c reductions (mean±SD: − 1.27± 1.96%) compared with the maintenance group-1 RAI injection/day (mean±SD: − 0.72± 1.66%) (p=0.0459), without a significant increase in BW and body mass index. Conclusion: The insulin glulisine intensification regimen showed glycemic target achievement and can be considered a therapeutic tool in the management of T2DM patients.
- 1 May 2022
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 15, 1495-1503
Open AccessReal-World Analysis of Rapid-Acting Insulin Analog Use and Its Blood Glucose Lowering Effect in Patients with Type 2 Diabetes Mellitus: Results from PASSION Disease Registry in Korea
Purpose: Although rapid-acting insulins (RAIs) are used frequently in Korean clinical settings, evidence on their use is limited. This study explores the pattern and clinical effectiveness of the use of RAIs in Korean patients with type 2 diabetes mellitus (T2DM). Patients and Methods: This non-interventional, observational study enrolled patients (aged > 18 years) with T2DM who were prescribed RAIs. The pattern of use and effectiveness of RAI analogs were evaluated over 6 months. Results: A total of 299/451 patients were analyzed. Approximately 90% (n/N=270/299) of the patients received insulin glulisine, which significantly reduced their levels of glycated hemoglobin (HbA1c: n=270, mean± standard deviation [SD]; − 1.16± 6.02%, p=0.0017), fasting plasma glucose (n=40; mean±SD: − 54.9± 90.89 mg/dl, p=0.0005), and post prandial blood glucose (n=35, mean±SD: − 89.46± 105.68 mg/dl, p< 0.0001) at 6 months, with a corresponding increase in body weight (BW) (n=197, mean±SD:1.45± 3.64 kg, p< 0.0001). At 6 months, more patients receiving an intensive regimen (basal insulin+≥ 2 RAI injections/day) had HbA1c < 7% than those receiving a non-intensive regimen (basal insulin+1 RAI injection/day) (20.69% vs 7.46%; p=0.0333); the corresponding reduction in HbA1c was also higher in patients receiving the intensive regimen (p< 0.0001). About one-fourth patients (n/N=22/95) were switched to the intensive regimen (from 1 to ≥ 2 RAI injections/day), and only 4.41% (n/N=9/204) of the patients were switched to 1 RAI injection/day. The patients receiving the intensive regimen showed higher levels of HbA1c reductions (mean±SD: − 1.27± 1.96%) compared with the maintenance group-1 RAI injection/day (mean±SD: − 0.72± 1.66%) (p=0.0459), without a significant increase in BW and body mass index. Conclusion: The insulin glulisine intensification regimen showed glycemic target achievement and can be considered a therapeutic tool in the management of T2DM patients.
- Open Access
- 30 November 2021
- Published by Korean Diabetes Association in Diabetes & Metabolism Journal
- Vol. 45 (6) , 972-973
Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2021;45:698-707)
- 30 November 2021
- Published by Korean Diabetes Association in Diabetes & Metabolism Journal
- Vol. 45 (6) , 972-973
Open AccessAlbuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2021;45:698-707)